Analyst Research

Report Title Price
Thomson Reuters Stock Report - ISU ABXIS COMPANY LIMITED (086890-KQ)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Isu Abxis Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
Wright Investors Service Comprehensive Report for ISU Abxis Company Limited
Provider: Wright Reports
$380.00
Buy
ISU ABXIS Co.,Ltd. (086890) - Financial Analysis Review
Provider: GlobalData
$125.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

ISU ABXIS Co., Ltd. Announces KFDA Approval


Monday, 13 Feb 2012 01:07am EST 

ISU ABXIS Co., Ltd. announced that it has received an approval from Korea Food & Drug Administration (KFDA) to start the phase 2 clinical testing for safety and efficiency of ISU303. 

Latest Developments for Isu Abxis Co Ltd

Latest Key Developments in Pharmaceuticals

Company Quote

Isu Abxis Co Ltd
(086890.KQ)
10500.0
50.0 +0.48%
16 May 2013